Stephens Downgrades 10x Genomics to Equal Weight
Stephens has downgraded 10x Genomics, Inc. from Overweight to Equal Weight, setting a price target of $65.
Stocks · News reference
10x Genomics Announces Participation in 2026 Jefferies Global Healthcare Conference
10x Genomics, Inc. announced that its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in London on November 17, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Single Cell Sequencing Market Forecast to 2035: Services, Technologies, End-users, Applications, and Regions | 15% CAGR Drives Drug Discovery and Precision Medicine Growth
The global single cell sequencing market is estimated at USD 1.38 billion and is projected to expand at a 15% CAGR through 2035, driven by advances in genomics, declining sequencing costs, and wider adoption in drug discovery, diagnostics, and precision medicine. North America is expected to account for approximately 50% of the market, with academic institutions representing the largest end-user segment at 60%. Key challenges include data processing requirements, quality management, and workflow costs.
TD Cowen Maintains Hold on 10x Genomics, Raises Price Target to $70
TD Cowen analyst Dan Brennan maintains 10x Genomics (NASDAQ:TXG) with a Hold and raises the price target from $47 to $70.